188 related articles for article (PubMed ID: 15332087)
21. Characterization of a double (amyloid precursor protein-tau) transgenic: tau phosphorylation and aggregation.
Pérez M; Ribe E; Rubio A; Lim F; Morán MA; Ramos PG; Ferrer I; Isla MT; Avila J
Neuroscience; 2005; 130(2):339-47. PubMed ID: 15664690
[TBL] [Abstract][Full Text] [Related]
22. Aggressive amyloidosis in mice expressing human amyloid peptides with the Arctic mutation.
Cheng IH; Palop JJ; Esposito LA; Bien-Ly N; Yan F; Mucke L
Nat Med; 2004 Nov; 10(11):1190-2. PubMed ID: 15502844
[TBL] [Abstract][Full Text] [Related]
23. Human brain amyloidoses.
Gambetti P; Russo C
Nephrol Dial Transplant; 1998; 13 Suppl 7():33-40. PubMed ID: 9870435
[No Abstract] [Full Text] [Related]
24. Enhanced accumulation of phosphorylated alpha-synuclein in double transgenic mice expressing mutant beta-amyloid precursor protein and presenilin-1.
Kurata T; Kawarabayashi T; Murakami T; Miyazaki K; Morimoto N; Ohta Y; Takehisa Y; Nagai M; Ikeda M; Matsubara E; Westaway D; Hyslop PS; Harigaya Y; Kamiya T; Shoji M; Abe K
J Neurosci Res; 2007 Aug; 85(10):2246-52. PubMed ID: 17526016
[TBL] [Abstract][Full Text] [Related]
25. Deficient cerebral clearance of vasculotropic mutant Dutch/Iowa Double A beta in human A betaPP transgenic mice.
Davis J; Xu F; Miao J; Previti ML; Romanov G; Ziegler K; Van Nostrand WE
Neurobiol Aging; 2006 Jul; 27(7):946-54. PubMed ID: 16105708
[TBL] [Abstract][Full Text] [Related]
26. Deposition of mouse amyloid beta in human APP/PS1 double and single AD model transgenic mice.
van Groen T; Kiliaan AJ; Kadish I
Neurobiol Dis; 2006 Sep; 23(3):653-62. PubMed ID: 16829076
[TBL] [Abstract][Full Text] [Related]
27. Cystatin C modulates cerebral beta-amyloidosis.
Kaeser SA; Herzig MC; Coomaraswamy J; Kilger E; Selenica ML; Winkler DT; Staufenbiel M; Levy E; Grubb A; Jucker M
Nat Genet; 2007 Dec; 39(12):1437-9. PubMed ID: 18026102
[TBL] [Abstract][Full Text] [Related]
28. [Hereditary amyloidosis].
Ikeda S
Ryoikibetsu Shokogun Shirizu; 2000; (29 Pt 4):514-23. PubMed ID: 11032011
[No Abstract] [Full Text] [Related]
29. Current insights into molecular mechanisms of Alzheimer disease and their implications for therapeutic approaches.
Van Broeck B; Van Broeckhoven C; Kumar-Singh S
Neurodegener Dis; 2007; 4(5):349-65. PubMed ID: 17622778
[TBL] [Abstract][Full Text] [Related]
30. Accelerated amyloid deposition, neurofibrillary degeneration and neuronal loss in double mutant APP/tau transgenic mice.
Ribé EM; Pérez M; Puig B; Gich I; Lim F; Cuadrado M; Sesma T; Catena S; Sánchez B; Nieto M; Gómez-Ramos P; Morán MA; Cabodevilla F; Samaranch L; Ortiz L; Pérez A; Ferrer I; Avila J; Gómez-Isla T
Neurobiol Dis; 2005 Dec; 20(3):814-22. PubMed ID: 16125396
[TBL] [Abstract][Full Text] [Related]
31. Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis.
Gervais F; Paquette J; Morissette C; Krzywkowski P; Yu M; Azzi M; Lacombe D; Kong X; Aman A; Laurin J; Szarek WA; Tremblay P
Neurobiol Aging; 2007 Apr; 28(4):537-47. PubMed ID: 16675063
[TBL] [Abstract][Full Text] [Related]
32. Age-related evolution of amyloid burden, iron load, and MR relaxation times in a transgenic mouse model of Alzheimer's disease.
El Tannir El Tayara N; Delatour B; Le Cudennec C; Guégan M; Volk A; Dhenain M
Neurobiol Dis; 2006 Apr; 22(1):199-208. PubMed ID: 16337798
[TBL] [Abstract][Full Text] [Related]
33. Detection of age-dependent brain injury in a mouse model of brain amyloidosis associated with Alzheimer's disease using magnetic resonance diffusion tensor imaging.
Sun SW; Song SK; Harms MP; Lin SJ; Holtzman DM; Merchant KM; Kotyk JJ
Exp Neurol; 2005 Jan; 191(1):77-85. PubMed ID: 15589514
[TBL] [Abstract][Full Text] [Related]
34. Peripheral and central biodistribution of (111)In-labeled anti-beta-amyloid autoantibodies in a transgenic mouse model of Alzheimer's disease.
Bacher M; Depboylu C; Du Y; Noelker C; Oertel WH; Behr T; Henriksen G; Behe M; Dodel R
Neurosci Lett; 2009 Jan; 449(3):240-5. PubMed ID: 18786612
[TBL] [Abstract][Full Text] [Related]
35. Intraneuronal amyloid beta and reduced brain volume in a novel APP T714I mouse model for Alzheimer's disease.
Van Broeck B; Vanhoutte G; Pirici D; Van Dam D; Wils H; Cuijt I; Vennekens K; Zabielski M; Michalik A; Theuns J; De Deyn PP; Van der Linden A; Van Broeckhoven C; Kumar-Singh S
Neurobiol Aging; 2008 Feb; 29(2):241-52. PubMed ID: 17112635
[TBL] [Abstract][Full Text] [Related]
36. Cycloxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer's disease in a sex-dimorphic pattern.
Melnikova T; Savonenko A; Wang Q; Liang X; Hand T; Wu L; Kaufmann WE; Vehmas A; Andreasson KI
Neuroscience; 2006 Sep; 141(3):1149-62. PubMed ID: 16753269
[TBL] [Abstract][Full Text] [Related]
37. [Local forms of amyloidosis as a manifestation of age-related pathology: a new look at the problem].
Serov VV
Arkh Patol; 1994; 56(5):39-43. PubMed ID: 7695492
[TBL] [Abstract][Full Text] [Related]
38. Nonprogressive transgene-related callosal and hippocampal changes in PDAPP mice.
Valla J; Schneider LE; Gonzalez-Lima F; Reiman EM
Neuroreport; 2006 May; 17(8):829-32. PubMed ID: 16708023
[TBL] [Abstract][Full Text] [Related]
39. A highly insoluble state of Abeta similar to that of Alzheimer's disease brain is found in Arctic APP transgenic mice.
Philipson O; Hammarström P; Nilsson KP; Portelius E; Olofsson T; Ingelsson M; Hyman BT; Blennow K; Lannfelt L; Kalimo H; Nilsson LN
Neurobiol Aging; 2009 Sep; 30(9):1393-405. PubMed ID: 18192084
[TBL] [Abstract][Full Text] [Related]
40. Alzheimer's disease from the perspective of the systemic and localized forms of amyloidosis.
Castaño EM; Frangione B
Brain Pathol; 1991 Jul; 1(4):263-71. PubMed ID: 1669716
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
